Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation

References

• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699.
   PubMed Web of Science ®Google Scholar
• Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. working group report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104(6):1136–1142.
   PubMed Web of Science ®Google Scholar
• Verna EC, Patel YA, Aggarwal A, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20(2):333–347.
   PubMed Web of Science ®Google Scholar
• Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):493–500.
   PubMed Web of Science ®Google Scholar
• Lai Q, Nicolini D, Inostroza Nunez M, et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score. Ann Surg. 2016;264(5):787–796.
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265(3):557–564.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Firl DJ, Hashimoto K, et al. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol. 2017;2(8):595–603.
   PubMed Web of Science ®Google Scholar
• Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18(5):1206–1213.
   PubMed Web of Science ®Google Scholar
• Chang Y, Cho Y, Lee JH, et al. Comparison of models for tumor recurrence after liver transplantation for the patients with hepatocellular carcinoma: a multicenter long-term follow-up study. Cancers (Basel). 2019;11:9.
   Web of Science ®Google Scholar
• Donne R, Saroul-Ainama M, Cordier P, Celton-Morizur S, Desdouets C. Polyploidy in liver development, homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17(7):391–405.
   PubMed Web of Science ®Google Scholar
• Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol. 2011;27:585–610.
   PubMed Web of Science ®Google Scholar
• Wang MJ, Chen F, Lau JTY, Hu YP. Hepatocyte polyploidization and its association with pathophysiological processes. Cell Death Dis. 2017;8(5):e2805.
   PubMed Web of Science ®Google Scholar
• Gentric G, Maillet V, Paradis V, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125(3):981–992.
   PubMed Web of Science ®Google Scholar
• Yamada T, Sogawa K, Kim JK, et al. Increased polyploidy, delayed mitosis and reduced protein phosphatase-1 activity associated with excess copper in the Long Evans Cinnamon rat. Res Commun Mol Pathol Pharmacol. 1998;99(3):283–304.
   PubMedGoogle Scholar
• Toyoda H, Bregerie O, Vallet A, et al. Changes to hepatocyte ploidy and binuclearity profiles during human chronic viral hepatitis. Gut. 2005;54(2):297–302.
   PubMed Web of Science ®Google Scholar
• Lin H, Huang YS, Fustin JM, et al. Hyperpolyploidization of hepatocyte initiates preneoplastic lesion formation in the liver. Nat Commun. 2021;12(1):645.
   PubMed Web of Science ®Google Scholar
• Bou-Nader M, Caruso S, Donne R, et al. Polyploidy spectrum: a new marker in HCC classification. Gut. 2020;69(2):355–364.
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429.
   PubMed Web of Science ®Google Scholar
• Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45(2):246–253.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–2593.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15.
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Mak TW, Ohashi PS. Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends Pharmacol Sci. 2010;31(8):356–363.
   PubMed Web of Science ®Google Scholar
• Mano Y, Yoshizumi T, Yugawa K, et al. Lymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2018;24(11):1603–1611.
   PubMed Web of Science ®Google Scholar
• Xu X, Ling Q, Wang J, et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population. Int J Cancer. 2016;138(3):620–629.
   PubMed Web of Science ®Google Scholar
• Ismael MN, Forde J, Milla E, Khan W, Cabrera R. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation. Biomed Res Int. 2019;2019:7284040.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128–139.
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994e983; quiz e914-985.
   PubMed Web of Science ®Google Scholar
• Zhang AB, Zhang ZH, Zhang J, et al. Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation. Hepatobiliary Pancreat Dis Int. 2019;18(3):223–227.
   PubMed Web of Science ®Google Scholar
• Yang Z, Luo FZ, Wang S, et al. Alpha-fetoprotein and (18) F-FDGstandard uptake value predict tumor recurrence after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis: preliminary experience. Hepatobiliary Pancreat Dis Int. 2020;19(3):229–234.
   PubMed Web of Science ®Google Scholar
• Miyaoka Y, Ebato K, Kato H, Arakawa S, Shimizu S, Miyajima A. Hypertrophy and unconventional cell division of hepatocytes underlie liver regeneration. Curr Biol. 2012;22(13):1166–1175.
   PubMed Web of Science ®Google Scholar
• Tanami S, Ben-Moshe S, Elkayam A, Mayo A, Bahar Halpern K, Itzkovitz S. Dynamic zonation of liver polyploidy. Cell Tissue Res. 2017;368(2):405–410.
   PubMed Web of Science ®Google Scholar
• Xie H, Zhang L, Guo D, et al. Protein profiles of pretransplant grafts predict early allograft dysfunction after liver transplantation from donation after circulatory death. Transplantation. 2020;104(1):79–89.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou W, Yin S, et al. Blocking Triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198–214.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–2046.
   PubMed Web of Science ®Google Scholar
• Huang CY, Wang Y, Luo GY, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in Hepatocellular carcinoma. J Immunother. 2017;40(9):323–333.
   PubMed Web of Science ®Google Scholar
• Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability–an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–228.
   PubMed Web of Science ®Google Scholar
• Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet. 2018;50(8):1189–1195.
   PubMed Web of Science ®Google Scholar
• Wangsa D, Quintanilla I, Torabi K, et al. Near-tetraploid cancer cells show chromosome instability triggered by replication stress and exhibit enhanced invasiveness. FASEB J. 2018;32(7):3502–3517.
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–1140.
   PubMed Web of Science ®Google Scholar
• Lee IC, Huang YH, Chau GY, et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. 2013;133(12):2895–2902.
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684.
   PubMed Web of Science ®Google Scholar
• Aranda F, Chaba K, Bloy N, et al. Immune effectors responsible for the elimination of hyperploid cancer cells. Oncoimmunology. 2018;7(8):e1463947.
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Gonzalez S, Lopez-Larrea C, Kroemer G. Immunosurveillance of malignant cells with complex karyotypes. Trends Cell Biol. 2017;27(12):880–884.
   PubMed Web of Science ®Google Scholar
• Lin YH, Zhang S, Zhu M, et al. Mice with increased numbers of polyploid hepatocytes maintain regenerative capacity but develop fewer hepatocellular carcinomas following chronic liver injury. Gastroenterology. 2020;158(6):1698–1712e1614.
   PubMed Web of Science ®Google Scholar
• Sladky VC, Knapp K, Szabo TG, et al. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep. 2020;21(12):e50893.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou K, Luo X, et al. The polyploid state plays a tumor-suppressive role in the liver. Dev Cell. 2018;44(4):447–459e445.
   PubMed Web of Science ®Google Scholar
• Zhang S, Nguyen LH, Zhou K, et al. Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting regeneration. Gastroenterology. 2018;154(5):1421–1434.
   PubMed Web of Science ®Google Scholar
• Gjelsvik KJ, Besen-McNally R, Losick VP. Solving the polyploid mystery in health and disease. Trends Genet. 2019;35(1):6–14.
   PubMed Web of Science ®Google Scholar
• Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74(2):442–457.
   PubMed Web of Science ®Google Scholar
• Firl DJ, Sasaki K, Agopian VG, et al. Charting the path forward for risk prediction in liver transplant for hepatocellular carcinoma: international validation of HALTHCC among 4089 patients. Hepatology. 2020;71(2):569–582.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol. 2020;73(2):342–348.
   PubMed Web of Science ®Google Scholar